SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060400
Filing Date
2024-05-15
Accepted
2024-05-15 16:02:29
Documents
58
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20240331.htm   iXBRL 10-Q 1705936
2 EX-10.1 spro-ex10_1.htm EX-10.1 120913
3 EX-10.4 spro-ex10_4.htm EX-10.4 51525
4 EX-31.1 spro-ex31_1.htm EX-31.1 10546
5 EX-31.2 spro-ex31_2.htm EX-31.2 10693
6 EX-32 spro-ex32.htm EX-32 8441
  Complete submission text file 0000950170-24-060400.txt   7214618

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spro-20240331.xsd EX-101.SCH 1310424
61 EXTRACTED XBRL INSTANCE DOCUMENT spro-20240331_htm.xml XML 903157
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 24950194
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)